Loading…
← CockpitCompetitor Analysis › 1521.HK Frontage Holdings Corp.Open in the cockpit ↗

Frontage Holdings Corp.1521.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Momentum leader 99
Mkt cap
$542M
US dollars, full cap
Free float
25%
of shares outstanding
$/day
$903,761
20-day average traded
Fwd P/E
24.6×
forward earnings
ROIC−WACC
-3.7 pp
WACC 7.6%
Hurdle
-1 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · HKDHK$2.08
1D+0.2%
1W-0.5%
1M+93.1%
3M+81.3%
6M+112.8%
YTD+108.5%
1Y+66.8%
ATR %4.1%
52w lowhigh6.1% off high

What Frontage does

Employees: 1,523

Frontage at a glance

Size Frontage (1521.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $542M, the 727th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$2.08 on 18 Nov 2026.

Performance Over six months the shares gained 112.8%, against -19.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — highest of 19 in its peer set.

Growth Revenue grew 10.3% over the last twelve months (peer median +3.9%); the operating margin is 7.9% (peer median -108.5%).

Valuation It trades at 24.6× forward earnings against a peer median of 29.9× (4th cheapest of 7).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.7 points below its cost of capital (7.6% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 20261521.HK 210Peer median 81
Six months, rebased to 100: Frontage against the median of its 20 peers (local-currency closes).

Frontage financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$2.17BHK$2.00BHK$1.99BHK$2.03BHK$1.96B
Revenue growth—+1%-2%+4%—
Gross profitHK$561MHK$539MHK$545MHK$614MHK$698M
EBITDAHK$452MHK$397MHK$356MHK$432MHK$493M
Net incomeHK$83.0MHK$53.0MHK$6.17MHK$84.6MHK$202M
Free cash flowHK$255MHK$219MHK$73.4MHK$130MHK$113M
Capital expenditureHK$111MHK$90.9MHK$202MHK$166MHK$376M
Total debtn/aHK$993MHK$1.20BHK$1.13BHK$922M

Quarterly statements and history in the cockpit →

Frontage competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%+100%CLYMWVE300871SANA300404300318GNFT1672FDMT6586SRZNCBIO1521.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Frontage is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×200×400×300871300404GNFT3008586032551521.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Frontage is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%300404GNFT6882471521.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Frontage is the large dot.

Frontage competitors and peer comparison

How Frontage compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Frontage against its 20 peers (data as of 18 Nov 2026)
Measure1521.HKPeer medianRank in peer set
1-month return+93.1%-15.3%highest of 21
6-month return+112.8%-19.4%highest of 19
Distance from 52-week high-6.1%-49.8%highest of 21
Revenue growth (TTM)+10.3%+3.9%7th highest of 16
Operating margin7.9%-108.5%2nd highest of 17
Forward P/E24.6×29.9×4th cheapest of 7
Growth the price implies (Req g, 7 yrs)14.3%31.9%least demanding of 4
Growth delivered (Del g)+15.4%+27.2%2nd lowest of 4
Hurdle (Req g minus delivered)-1.1 pp+4.7 pp2nd least demanding of 4
ROIC minus cost of capital-3.7 pp-3.9 pp6th highest of 12
EV / EBITDA11.2×n/a—
Net debt / EBITDA1.8×n/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Frontage 1521.HKHong Kong$542M+113%+10%8%24.6×14.3%+15.4%
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%n/an/an/a
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%11.7×n/an/a
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Boji Medical Technology 300404.SZChina$561M-6%+32%4%69.3×31.9%+27.2%
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%n/an/an/a
Genfit GNFT.PAFrance$571M+22%+28%-130%431.5×39.8%+143.5%
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%n/an/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%n/an/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%n/an/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%21.5×n/an/a
Sinotherapeutics 688247.SSChina$494M-19%-17%0%n/a29.4%+7.0%
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%n/an/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%37.5×n/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%n/an/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%22.3×n/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%n/an/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%n/an/an/a

Questions

Which companies are Frontage's closest peers?
The cockpit's peer set: Climb Bio (CLYM), Wave Life Sciences (WVE), Hvsen Biotechnology (300871.SZ), Sana Biotechnology (SANA), Boji Medical Technology (300404.SZ), Beijing Bohui Innovation Biotechnology (300318.SZ), Genfit (GNFT.PA), Ascletis Pharma (1672.HK).
Is Frontage expensive compared with its peers?
On forward p/e it trades at 24.6× against a peer median of 29.9×, 4th cheapest of 7 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Frontage stock performed?
Over six months to 18 Nov 2026 the shares returned +112.8% against -19.4% for the median peer; over one year +66.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.